A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Status:
Withdrawn
Trial end date:
2017-07-19
Target enrollment:
Participant gender:
Summary
Abbreviated Title: An explorative Phase II study of Anti-PD-1 (Pembrolizumab) in patients
with advanced melanoma (ADAPTeM)
Trial Phase: Phase II
Clinical Indication: Stage III unresectable/stage IV metastatic melanoma
Trial Type: Exploratory Phase II trial
Route of administration: Intravenous Pembrolizumab, 200mg, 3weekly
Trial Blinding: Unblinded; open label Phase II study
Treatment Groups: All participants treated with Pembrolizumab, 200mg iv, 3weekly
Number of trial subjects: 40
Estimated duration of trial: 24 months
Duration of Participation: 24 months